drugset / Trial / NCT00546234

Tiotropium for Smoking Asthmatics Study

NCT00546234

Phase 4 Withdrawn University of Alberta
Non-randomizedCrossoverOpen-labelTreatment

Summary

The study's research questions concern the appropriateness of use of tiotropium for patients with asthma who are current smokers. It is suggested that patients with asthma who smoke, may in fact share similarities with patients with chronic obstructive pulmonary disease (COPD). Because of this, the study will determine whether this sub-group of patients would in fact benefit from therapy currently approved and marketed for COPD patients.

Timeline

Start
2007-11
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 6 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled
Subject salmeterol xinafoate Unknown 6 ug Inhaled
Subject salmeterol xinafoate Unknown 12 ug Inhaled

Indications